Current vascular pharmacology

Keyphrases

Publications

2023

Detopoulou P, Letsiou S, Nomikos T, Karagiannis A, Pergantis Sa, Pitsavos C, Panagiotakos Db, Antonopoulou S
Selenium, selenoproteins and 10-year cardiovascular risk: Results from the ATTICA Study. Current vascular pharmacology (2023)
Stergios A Polyzos, Jannis Kountouras
Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship? Current vascular pharmacology (2023)
Francesco Salis, Antonella Palimodde, Samuele Rundeddu, Antonella Mandas
STOPP/START Anti-aggregation and Anticoagulation Alerts in Atrial Fibrillation. Current vascular pharmacology (2023)
Xiaoxu Fu, Xiujuan Zhou, Ya Liu, Yuanhong Lei, Hongyan Xie, Yulin Leng, Hong Gao, Chunguang Xie
Preliminary Study of the Distinctive Mechanism of Shenqi Compound in Treating Rats with Type 2 Diabetes Mellitus by Comparing with Metformin. Current vascular pharmacology (2023)
Jin Xu, Liyuan Zhu, Yingying Xie, Miao Zhang, Zixi Xiao, Rongkai Su, Tie Wen, Ling Liu
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial. Current vascular pharmacology (2023)
Joana da Silva Rocha, Luís Guedes-Martins, Ana Cunha
Twin Anemia-Polycythemia Sequence (TAPS): From Basic Research to Clinical Practice. Current vascular pharmacology (2023)
Laith Al-Eitan, Mishael Alkhawaldeh
MDMB-FUBINACA Influences Brain Angiogenesis and the Expression of VEGF, ANG-1, and ANG-2. Current vascular pharmacology (2023)
Kosmas I Paraskevas, Joana Ferreira, Armando Mansilha
Aortic Intima-Media Thickness in Neonates of Mothers with Gestational Diabetes Mellitus: An Opportunity for Early Initiation of Vascular Disease Prevention. Current vascular pharmacology (2023)
Jing Yang, Shuling Rong
The emerging role of CircRNAs in Atherosclerosis. Current vascular pharmacology (2023)
Athyros Vg, Sfikas G, Koumaras C, Athyrou V
A pilot study suggesting several benefits of alpha lipoic acid in patients with diabetes. Current vascular pharmacology (2023)
Tolga Demir, Mazlum Sahin, Fatma Tugba Ilal Mert, Fatma Sarac
Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury. Current vascular pharmacology (2023)
Valentina Lopera, Jaime Andrés Pereañez, Pedro Amariles
Drugs as Possible Triggers of Takotsubo Cardiomyopathy- Update 2022: Systematic Review. Current vascular pharmacology (2023)
Haijing Guan, Jingwen Sun, Xiuying Liang, Wenjuan Yao
Protective role of cytochrome c oxidase 5A (COX5A) against mitochondrial disorder and oxidative stress in VSMC phenotypic modulation and neointima formation. Current vascular pharmacology (2023)
Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A Batais, Turky H Almigbal, Ali Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A ElToukhy, Naji Kholaif, Abdulhalim J Kinsara, Manal Al-Kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Hani Altaradi, Khalid F Alhabib
The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): Design, Rationale, and Preliminary Results. Current vascular pharmacology (2023)
Stergios A Polyzos, Jannis Kountouras
Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship? Current vascular pharmacology (2023)
Andrej Janez, Rok Herman, Pavel Poredos, Dimitri P Mikhailidis, Ales Blinc, Miso Sabovic, Katica Bajuk Studen, Mateja Kaja Jezovnik, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle
Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management. Current vascular pharmacology (2023)
Ali Doğan Dursun, Ersin Saricam, Hakan Erdem, Gulcin Turkmen Sariyildiz, Esref Umut Ozyer, Engin Bozkurt, Erdogan Ilkay, Ömer Faruk Cantekin
Clinical and laboratory evaluation of acute pericarditis associated with antinuclear antibodies positivity. Current vascular pharmacology (2023)
Chao Gu, Ting Zhang, Yuan Gao, Xiaojia Li, Xiaorong Yuan, Qiwen Wang, Hong Liu, Ruilan Han, Gang Li
Lanthanum Hydroxide and Chronic Kidney Disease Mineral and Bone Disorder: A Rat Model. Current vascular pharmacology (2023)
Xueqi Wan, Jinfan Tian, Peng Hao, Jing Zhang, Yuquan Zhou, Changjiang Ge, Xiantao Song
The cGAS-STING Pathway: A Ubiquitous Checkpoint Perturbing Myocardial Attributes. Current vascular pharmacology (2023)
Ales Blinc, null Schernthaner Gh, null Poredoš P, null Anagnostis P, null Jensterle M, Bajuk Studen K, null Antignani Pl, null Mikhailidis Dp, null Šabović M
Testosterone and peripheral arterial disease. Current vascular pharmacology (2023)
Aleksandra Zeljkovic, Marija Mihajlovic, Sanja Vujcic, Azra Guzonjic, Jelena Munjas, Aleksandra Stefanovic, Jelena Kotur-Stevuljevic, Manfredi Rizzo, Natasa Bogavac-Stanojevic, Jelena Gagic, Jelena Kostadinovic, Jelena Vekic
The prospect of genomic, transcriptomic, epigenetic and metabolomic biomarkers for the personalized prevention of type 2 diabetes and cardiovascular diseases. Current vascular pharmacology (2023)
Djordje S Popovic, Theocharis Koufakis, Nikoloas Papanas
The Recent Trends in All-cause and Cardiovascular Mortality among People with Type 1 Diabetes Mellitus - Success is Still Far Away, and We Must Do Better! Current vascular pharmacology (2023)
Luis Cassinotti, María Guil, Liliana Bianciotti, Marcelo Vatta
Role of Brain Endothelin Receptor Type B (ETB) in the Regulation of Tyrosine Hydroxylase in the Olfactory Bulb of DOCA-Salt Hypertensive Rats. Current vascular pharmacology (2023)
Carlo Cervellati, Alessandro Trentini, Valentina Rosta, Giovanni Zuliani, Francesco Vieceli Dalla Sega, Francesca Fortini, Paola Rizzo, Paolo Cimaglia, Gianluca Campo
A Nutraceutical Compound Containing a Low Dose of Monacolin K, Polymethoxyflavones, Phenolic Acids, Flavonoids, and Hydroxytyrosol Improves HDL Functionality. Current vascular pharmacology (2023)
Poredoš P, Schernthaner Gh, Blinc A, Mikhailidis Dp, Antignani Pl, Anagnostis P, Jensterle M, Bajuk Studen K, Šabović M, Ježovnik Mk
Endocrine Disorders and Peripheral Arterial Disease: A Series of Reviews. Current vascular pharmacology (2023)
Rose Mary Lisboa da Silva, Lucas Espindula Borges
Neutrophil-lymphocyte ratio and red blood cell distribution width in patients with atrial fibrillation and rheumatic valve disease. Current vascular pharmacology (2023)
Pinelopi Triantafyllidou, Anna Papadopoulou, Eirini Thymara, Vassiliki Papaevangelou, George Mastorakos, Anastasios Papadimitriou, Sophia Kalantaridou, Constanine A Stratakis, Efthymia Alexopoulou
Aortic Intima-Media Thickness is Increased in Neonates of Mothers with Gestational Diabetes Mellitus: The Role of Thioredoxin-Interacting Protein as a Marker of Oxidative Stress. Current vascular pharmacology (2023)
Antonis A Manolis, Theodora A Manolis, Helen Melita, Antonis S Manolis
Features of a Balanced Healthy Diet With Cardiovascular and Other Benefits. Current vascular pharmacology (2023)
Jing Cui, Yiwen Li, Mengmeng Zhu, Yanfei Liu, Yue Liu
Analysis of the Research Hotspot of Exosomes in Cardiovascular Disease: A Bibliometric-based Literature Review. Current vascular pharmacology (2023)
Antonio Siniscalchi, Piergiorgio Lochner, Giovambattista De Sarro, Luca Gallelli
Is Colchicine Involved in Managing Stroke? Current vascular pharmacology (2023)
Raheeq Hadi Ahmed, Bussma Ahmed Bugis
Implementation and Importance of Cardiac Rehabilitation for Cardiac Patients in Saudi Arabia: A Systematic Review. Current vascular pharmacology (2023)
Goran Koracevic, Slađana Mićić, Milovan Stojanovic, Nenad Bozinovic, Dragan Simic, Dragan Lović, Nebojsa Krstic, Ružica Janković Tomašević
In many patients with hypertensive left ventricular hypertrophy, a beta-blocker is needed because of the prevalent myocardial ischemia. Current vascular pharmacology (2023)
Panagiotis Anagnostis, Dimitri P Mikhailidis, Ales Blinc, Mojca Jensterle, Mateja K Ježovnik, Gerit-Holger Schernthaner, Pier Luigi Antignani, Katica Bajuk Studen, Miso Šabović, Pavel Poredos
The Effect of Menopause and Menopausal Hormone Therapy on the Risk of Peripheral Artery Disease. Current vascular pharmacology (2023)
Shuangbo Liu, Janine Eckstein, Anna Lam, Asim Cheema
Acetylsalicylic Acid (aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current vascular pharmacology (2023)
Kosmas I Paraskevas, Piotr Musialek, Dimitri P Mikhailidis, Gregory Y H Lip
The Fundamental Role of Medical Treatment in the Prevention of CarotidRelated Strokes: Insights from a Multispecialty Consensus Document. Current vascular pharmacology (2023)
Antonis A Manolis, Theodora A Manolis, Helen Melita, Antonis A Manolis
Role of Vitamins in Cardiovascular Health: Know Your Facts - Part 1. Current vascular pharmacology (2023)
Katica Bajuk Studen, Simona Gaberscek, Katja Zaletel, Ales Blinc, Miso Sabovic, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle, Dimitri P Mikhailidis, Pavel Poredos
Thyroid Disorders and Peripheral Arterial Disease. Current vascular pharmacology (2023)
Hussein Al Sudani, Samir Shah, Kevin Bryan Lo, Hani Essa, Ammaar Wattoo, Lucas Angelim, Sophia Brousas, Isabel Whybrow-Huppatz, Shaitalya Vellanki, Rajiv Sankaranarayanan, Janani Rangaswami
"Renalism" with Renin Angiotensin Aldosterone System Inhibitor use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review. Current vascular pharmacology (2023)
Antonis A Manolis, Theodora A Manolis, Helen Melita, Antonis A Manolis
Role of Vitamins in Cardiovascular Health: Know Your Facts-Part 2. Current vascular pharmacology (2023)
Tábata de Paula Facioli, Stella Vieira Philbois, Jens Tank, Ada Clarice Gastaldi, Bruno Augusto Aguilar, Ana Catarine da Veiga Oliveira, Lucas Dalvit Ferreira, Hugo Celso Dutra de Souza
Aerobic Physical Exercise is Essential for Cardiac Autonomic Regulation in Hypertensive Patients Undergoing Chronic Treatment with Renin-Angiotensin System Inhibitors. Current vascular pharmacology (2023)
Herman R, Janez A, Mikhailidis Dp, Poredos P, Blinc A, Sabovic M, Bajuk Studen K, Schernthaner Gh, Anagnostis P, Antignani Pl, Jensterle M
Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency. Current vascular pharmacology (2023)
Hanan AlBackr, Khalid F Alhabib, Kadhim Sulaiman, Amal Jamee, Mohamed Sobhy, Salim Benkhedda, Sobhi Dada, Ayman Hammoudeh, Habib Gamra, Ahmed Al-Motarreb, Fahad Alkindi, Mohammad I Amin, Magdi G Yousif, Hasan A Farhan, Nadia Fellat, Wael Almahmeed, Mohammad Al Jarallah, Prashanth Panduranga, Magdy Abdelhamid, Ihab Ghaly, Dahlia Djermane, Ahcene Chibane, Hadi Skouri, Mohamad Jarrah, Hassen Amor, Nora K Alsagheer, Mohammed A Hozayen, Hosameldin S Ahmed, Muhammad Ali, Anhar Ullah, Ayman Al Saleh, Faiez Zannad
Clinical Features, Socioeconomic Status, Management, and Outcomes of Acute Heart Failure: PEACE MENA Registry Phase I Results. Current vascular pharmacology (2023)
Ting Chen, Yunlei Deng, Rong Gong
Cardiovascular Protection of Aspirin in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. Current vascular pharmacology (2023)
Xinxin Chen, Xiaolong Chen
The Role of TRIM Proteins in Vascular Disease. Current vascular pharmacology (2023)
Felice Gragnano, Antonio Capolongo, Paolo Calabrò
P2Y12 Inhibitor or Aspirin Monotherapy in Patients with Coronary Artery Disease: is it Time for a Paradigm Shift? Current vascular pharmacology (2023)
Xiuying Tang, Runjun Li
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention. Current vascular pharmacology (2023)
Antonietta Gigante, Rosario Cianci
Dual blockade of the renin-angiotensin system in glomerular diseases: is it recommended?. Current vascular pharmacology (2023)
Chrysoula Boutari, Fotios Siskos, Vasilios G Athyros
Hypertension-mediated organ damage detection: The earlier the hypertension treatment, the better. Current vascular pharmacology (2023)
Rodrigo Damián García, Joana Antonela Asensio, Diahann Jeanette Perdicaro, María de Los Ángeles Peral
Response to Athyros and colleagues: Inflammation and LDL reduction. Current vascular pharmacology (2023)

volume 21, number 3, 2023

Dimitris Benas, Helen Triantafyllidi, Dionyssia Birmpa, Anastasia Fambri, Antonios Schoinas, Ioannis Thymis, Gavriela Kostelli, Ignatios Ikonomidis
Hypertension-Mediated Organ Damage In Young Patients With First-Diagnosed And Never Treated Systolic Hypertension. Current vascular pharmacology 21 (3) (2023)